Basit öğe kaydını göster

dc.contributor.authorTascanov, Mustafa Begenc
dc.contributor.authorYilmaz, Ozcan
dc.date.accessioned2020-06-21T13:05:37Z
dc.date.available2020-06-21T13:05:37Z
dc.date.issued2019
dc.identifier.issn1309-0720
dc.identifier.issn1309-2014
dc.identifier.urihttps://doi.org/10.4328/JCAM.5853
dc.identifier.urihttps://hdl.handle.net/20.500.12712/11226
dc.descriptionWOS: 000451875800017en_US
dc.description.abstractAim: Decreased cystatin C increases proteolytic effects of cathepsin contributing to plaque rupture. We aimed to Investigate the association of cystatin C levels with in-hospital and post-discharge cardiac events in patients with acute myocardial infarction (AMI). Material and Method: We included 85 patients with AMI. Patients with cancer, systemic diseases, increased creatinine, active infection or aortic aneurysm were excluded. Demographic data, laboratory and echocardiographic parameters were analyzed. Serum cystatin C levels were measured in before coronary angiography. Results: Non-ST elevation myocardial infarction was determined in 32.94% of the patients. There were no differences between the normal and high cystatin C groups in terms of gender, diagnosis, obesity, hypertension, hyperlipidemia, cigarette smoking, Killip classification, preference of primary percutaneous coronary intervention or thrombolytic therapy, frequencies of culprit coronary arteries or the number of obstructed arteries. Diabetes mellitus was more frequent in the high cystatin C group. Complication rates after AMI were similar in both the normal and high cystatin C groups on the 5th day and the 12th month. Mean age was higher in the high cystatin C group. ESR, low density lipoprotein (LDL) and total cholesterol were found to be significantly higher in the high cystatin C group. The optimum cut-off values for ESR, LDL and total cholesterol were 11, 88.6, and 161.5, respectively; diagnostic accuracies were adequate. Discussion: The results of the study showed that ESR, LDL and total cholesterol were higher in high cystatin C group, but complications were similar in both groups. We concluded that cystatin C was not a predictor for post-AMI complications at 12th month.en_US
dc.language.isoengen_US
dc.publisherDerman Medical Publen_US
dc.relation.isversionof10.4328/JCAM.5853en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute Myocardial Infarctionen_US
dc.subjectCystatin Cen_US
dc.subjectComplicationen_US
dc.titleMay cystatin-c be associated with post-myocardial infarction complications?en_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume10en_US
dc.identifier.issue1en_US
dc.identifier.startpage76en_US
dc.identifier.endpage82en_US
dc.relation.journalJournal of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster